Pusztai L, Yau C, Wolf DM, Han HS, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell 2021 Jun 2. pii: S1535-6108(21)00275.
PMID: 34143979